Enfortumab Vedotin Reactions Reclassified as TEC, Not TEN
A JAAD analysis published October 12, 2026 reclassifies severe enfortumab vedotin cutaneous reactions as TEC rather than TEN, with implications for management and drug continuation.
Topic
Antibody Drug Conjugate
Topic
Antibody Drug Conjugate
Medicus Bets on Melanoma ADC After Pfizer Deal
Medicus has named its melanoma antibody-drug conjugate a 'strategic priority' after closing a deal with Pfizer, concentrating res…